艑URA has signalled an entry into the consumer diabetes space, offering a new glucose feature for its ring that uses insights from Dexcom鈥檚 over-the-counter (OTC) continuous glucose monitor (CGM) Stelo.
The integration between the Oura smart ring and Stelo is the culmination of a partnership between 艑URA and Dexcom in November 2024. The diabetes device giant invested $75m into Finland-based 艑URA to enable data flow between their respective products.
The Glucose feature on the Oura app will show daily glucose readings set against periods of meals, sleep, stress, and activity. Data will be extracted from Stelo, the first biosensor approved by the US Food and Drug Administration (FDA) for use without a prescription.
Oura will also provide insights to users on how glucose interacts with meals, stress, and daily movement. This, the ring developer says, will help patients learn lifestyle habits that help them maintain or achieve optimal glucose levels.
鈥淧ersonalised guidance and insights are essential for helping people understand how their lifestyle choices affect their body, while also encouraging them to make informed health decisions that can improve their overall quality of life,鈥� said Jake Leach, executive vice-president and chief operating officer at Dexcom.
The glucose feature was launched alongside Meals, an AI-powered tool that provides nutrition information from photographs of food.
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataWhen launched, Meals and Glucose will be available on iOS and Android for US-based Oura users, with plans to launch Meals internationally later this year.
The partnership between 艑URA and Dexcom has signalled a new chapter in the consumer health and medical device sector convergence.
艑URA is fast becoming a household name in the wearable technology sector, thanks to its smart ring. The device measures sleep, stress, and cardiovascular data, among others. It spurred the company to nearly double its annual sales in 2024 to reach around $500m, with 2.5 million rings sold worldwide.
Dexcom, meanwhile, is a significant player in the diabetes medical device market, occupying around 74% of the CGM market share in the US, according to analysis by GlobalData. Experts have previously said the partnership between the two companies has the potential to improve adherence and behaviour changes, both critical for long-term diabetes management.
One of the key financial aspects of the partnership was that both Dexcom and 艑URA would co-market and cross-sell each other鈥檚 products. That is indeed now a reality, with new and existing Oura members able to purchase Stelo directly from the smart ring developer for $99. The CGM can be bundled with or without a ring, representing a model example of consumer health and medtech product combination, though this is currently only available in the US.
